Reboxetine Treatment Reduces Hippocampal Gliosis in the P301S Tauopathy Mouse Model - PubMed
4 hours ago
- #Alzheimer's disease
- #neuroinflammation
- #reboxetine
- Reboxetine, a noradrenaline reuptake inhibitor, reduces hippocampal gliosis in P301S tauopathy mice.
- Noradrenaline deficit in Alzheimer's disease facilitates neuroinflammation, making reboxetine a potential therapeutic strategy.
- Treatment with reboxetine for 28 days in 9-month-old P301S mice reduced microglia and astrocyte activation in the hippocampus.
- Reboxetine shows promise in preventing neuroinflammatory damage in Alzheimer's disease, even at advanced stages.
- Previous studies also demonstrated reboxetine's beneficial effects in 5xFAD mice, another Alzheimer's disease model.